

August 22, 2019

The Massachusetts Department of Public Health (DPH) has been made aware of a current national shortage, and anticipated supply interruption, of APLISOL®, one of two purified-protein derivative (PPD) tuberculin products licensed by the U.S. Food and Drug Administration (FDA) for detecting TB infection. The APLISOL® shortage was announced by the Centers for Disease Control and Prevention (CDC). Limited availability of TUBERSOL®, the other FDA-licensed PPD tuberculin product, has also been reported. In an attempt to help providers and public health programs that currently use APLISOL® manage this situation, CDC has issued an advisory that suggests several operational strategies. Click [here](#) to access the full advisory with recommendations from the DPH.